FibroGen, a biotech company, experienced a setback as its leading candidate, Pamrevlumab, failed to meet the primary endpoint in a Phase III trial for non-ambulatory patients with Duchenne muscular dystrophy (DMD) on background corticosteroids. The LELANTOS-1 trial tested the candidate against a placebo and found that it missed the primary study endpoint of Performance of the Upper Limb 2.0 at the one-year mark compared to baseline. FibroGen's CEO Enrique Conterno expressed disappointment but confirmed that full results from this trial would be shared by FibroGen at an upcoming medical conference. Meanwhile, another Phase III trial is underway for ambulatory DMD patients with early results expected in Q3 2023.
Keywords: FibroGen, Pamrevlumab, Duchenne muscular dystrophy drug failure
Additional sentence: Despite being tested in multiple fibrosis-driven indications such as DMD and idiopathic pulmonary fibrosis (IPF), all three indications are still in Phase III trials and have yet to produce topline data.